CABA (Cabaletta Bio) Moat Score: 2/10 (As of Jun. 28, 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.03
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Moat Score?

Cabaletta Bio CABA +3.75% 34 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,402 Biotechnology companies, Cabaletta Bio ranks better than 58.06% on this metric.

Cabaletta Bio has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cabaletta Bio has No Moat: Cabaletta Bio is in the early stages of development with no established market leadership or significant intellectual property. The biotech sector's inherent risks and competition contribute to a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cabaletta Bio might have No Moat - Very weak/transient advantages.

Cabaletta Bio  (NAS:CABA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cabaletta Bio Moat Score Related Terms

CABA vs DNA, CADL, CLYM: Moat Score Comparison

For the Biotechnology subindustry, Cabaletta Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cabaletta Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabaletta Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Cabaletta Bio's Moat Score falls into.


CABA
34GF Score
Cabaletta Bio Inc CABA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cabaletta Bio (CABA) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cabaletta Bio ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Cabaletta Bio's Moat Score too high?
Cabaletta Bio's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Cabaletta Bio's value of 2 is 0% at this industry median. Based on the distribution chart, Cabaletta Bio ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Moat Score compare to DNA and CADL?
According to the Biotechnology industry distribution chart, Cabaletta Bio ranks #588 out of 1402 companies for Moat Score. This puts Cabaletta Bio in the upper half of its industry. The industry median Moat Score is 2.00. Cabaletta Bio's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cabaletta Bio's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabaletta Bio's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.03
Price